Co-delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition
Open Access
- 29 August 2017
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-11
Abstract
The poor intracellular uptake and non-specific binding of anticancer drugs into cancer cells are the bottlenecks in cancer therapy. Nanocarrier platforms provide the opportunities to improve the drug efficacy. Here we show a carbon-based nanomaterial nanodiamond (ND) that carried paclitaxel (PTX), a microtubule inhibitor, and cetuximab (Cet), a specific monoclonal antibody against epidermal growth factor receptor (EGFR), inducing mitotic catastrophe and tumor inhibition in human colorectal cancer (CRC). ND-PTX blocked the mitotic progression, chromosomal separation, and induced apoptosis in the CRC cells; however, NDs did not induce these effects. Conjugation of ND-PTX with Cet (ND-PTX-Cet) was specifically binding to the EGFR-positive CRC cells and enhanced the mitotic catastrophe and apoptosis induction. Besides, ND-PTX-Cet markedly decreased tumor size in the xenograft EGFR-expressed human CRC tumors of nude mice. Moreover, ND-PTX-Cet induced the mitotic marker protein phospho-histone 3 (Ser10) and apoptotic protein active-caspase 3 for mitotic catastrophe and apoptosis. Taken together, this study demonstrated that the co-delivery of PTX and Cet by ND enhanced the effects of mitotic catastrophe and apoptosis in vitro and in vivo, which may be applied in the human CRC therapy.Keywords
This publication has 58 references indexed in Scilit:
- Drugs that target dynamic microtubules: A new molecular perspectiveMedicinal Research Reviews, 2011
- In Vivo Imaging and Toxicity Assessments of Fluorescent Nanodiamonds in Caenorhabditis elegansNano Letters, 2010
- Nuclear EGFR contributes to acquired resistance to cetuximabOncogene, 2009
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal CancerNew England Journal of Medicine, 2009
- Nanotechnology, nanotoxicology, and neuroscienceProgress in Neurobiology, 2009
- Death through a tragedy: mitotic catastropheCell Death & Differentiation, 2008
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family membersOncogene, 2008
- Systemic Therapy for Colorectal CancerNew England Journal of Medicine, 2005
- Cell death by mitotic catastrophe: a molecular definitionOncogene, 2004